Table 3. Subgroup analyses for patients from two randomised studies (n=361): The hazard ratio gives the relative increase of the risk for disease progression following carboplatin therapy compared to cisplatin-based combination treatment. Inferiority of carboplatin has been observed in all investigated subgroups.

Subgroup	N pts	Hazard ratio for PFS [95% CI]
Lung metastases	29	1.4 [0.4–5.2]
No lung metastases	332	4.6 [2.5–8.7]
Lymph node metastases only	263	3.7 [1.9–7.3]
No lymph node metastases	98	3.6 [1.4–9.5]
Nonpulmonary visceral metastases	20	4.7 [0.5–49.5]
No nonpulmonary visceral metastases	341	3.5 [2.0–6.3]
Age <30 yearsa	59	2.7 [0.5–14.2]
Age 30–50 yearsa	221	2.8 [1.5–5.3]
Age >50 yearsa	56	12.9 [1.7–100.4]
Previous radiation (Yes)	310	2.8 [0.9–9.0]
Previous radiation (No)	51	3.7 [2.0–6.9]

PFS=progression-free survival.

^aAge missing in 25 patients.